Karlijn de Joode

5PUBLICATIONS
10CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersPharmacogenomics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Jul 11, 2026
Long-term survivors of melanoma after anti-PD-1 therapy demonstrate on-treatment increase in abundance of 4-1BB+ CD4 T cells in blood.

|Jun 24, 2026
Blood-based kinase activity profiling to predict response to immune checkpoint inhibitors in patients with advanced stage NSCLC: the prospective IOpener study.

|Feb 07, 2023
Suitability of tumor-associated antibodies as predictive biomarker for response to immune checkpoint inhibitors in patients with melanoma: a short report.

Karlijn de Joode, Sharon Veenbergen, Claudia Kransse

|Dec 01, 2021
Patients with primary brain tumors and COVID-19: A report from the Dutch Oncology COVID-19 Consortium.

Karlijn de Joode, Walter Taal, Tom J Snijders

|Jun 05, 2021
Prospective real-world study on the pharmacokinetics of pembrolizumab in patients with solid tumors.

Daan P Hurkmans, Sebastiaan D T Sassen, Karlijn de Joode

Pageof 1

Frequent Collaborators

3 joint publications

Reno Debets

3 joint publications

Ron H J Mathijssen

1 joint publications

Daan P Hurkmans

1 joint publications

Walter Taal